Professional Documents
Culture Documents
3rd LE Preventive-Medicine-II 2020-2021
3rd LE Preventive-Medicine-II 2020-2021
3rd LE Preventive-Medicine-II 2020-2021
A. Case Control
B. Cohort
C. Cross-sectional
D. Experimental
2. Which criterion best reflects the effects of cigarette cessation on lung cancer death?
A. biologic plausibility
B. (statistical) coherence
C. Dose response relations hip
D. Temporality
3. Which level of strength of association will be considered for a Relative Risk of 1.2?
A. Weak
B. Moderate
C. Strong
D. Very strong
18
16
Mortality Ratio
14
12
10
8
6
4
2
0
1 to 4 5 to 9 10 to 14 15 to 19 20 Plus Non-Smoker
4. Which criterion best reflects the effects of cigarette cessation on lung cancer death?
A. Biologic plausibility
B. (statistical) coherence
C. Dose response relationship
5. Which criterion demonstrates that under controlled conditions. modifying the exposure causes
a change in the outcome?
A. biologic plausibility
B. coherence
C. experiment
D. temporality
For numbers 6 and 7, choose the appropriate criterion that applies to the following table/graph from
the options below:
A. Biological plausibility
B. Dose response
C. Specificity
D. Temporality
6. Table 3. Mortality Ratios of Current Cigarette-Only Smokers, by Cause of Death in Eight Cohort
Studies.
20
18
Mortality Ratio
16
14
12
10
8
6
4
2
0
Non-Smoker 25 Plus 20 to 24 16 to 19 Under 16
8. In subdivided population, there is similarity in the distributions of the exposure and the outcome.
Therefore, those groups with a high rate of exposure have a high rate of outcome as well. Which
criteria DOES NOT apply?
A. consistency association
B. dose-response relationships
C. strength of association
D. temporality
10. In an experimental study, what is the variable usually altered by the experimenter/investigator?
A. Dependent variable
B. Independent variable
C. Intervening variable
D. Null variable
11. What type of variable is usually measured at the end of the experiment and demonstrates the
effects that other variables may have?
A. Dependent variable
B. Independent variable
C. Intervening variable
D. Null variable
12. If you were testing how well different cough preparations cleared mucus in the airways, what is
the independent (experimental) variable?
A. Cough preparations
B. Difficulty of breathing
C. Mucus clearing
D. Symptom relief
13. Which is the critical step in doing a Randomized Clinical Trial (RCT)?
A. Blinding
B. Follow-up
C. Randomization
D. Statistical Analysis
14. Which of the following is the most important advantage of conducting an RCT?
A. Ethical consideration is less prioritized.
B. Patients are les s likely to be lost to follow up.
C. Bias is avoided in allocation to exposure groups.
D. Can be done in a reasonably short period of time.
15. Which is defined as the degree to which study subjects adhere to an assigned treatment protocol
in RCTs?
A. Benefit
B. Compliance
C. Control
D. Flexibility
16. Who are NOT aware of what drug is given in Double Blinding in RCTs?
A. investigators and analysts
B. participants and analysts
C. participants and investigators
For numbers 17 -21, choose the Drug Trial Phase being described. Options may be used more than
once.
A. I
B. II
C. Ill
D. IV
For numbers 22 -24, choose the blinding method used. Options may be used more than once.
A. Single blind
B. Double blind
C. Triple blind
D. No blinding
28. Which of the following documents is mandatory to enroll a participant in a clinical research
study?
A. Case Report form
B. Informed Consent form
C. Patient Identification form
D. Protocol form
31. Which qualitative study design describes the lived experiences of the participants who have
been exposed to a unique situation?
A. Case study
B. Ethnography
C. Grounded theory
D. Phenomenology
32. Which qualitative study involves the immersion of the researcher into the culture of the study
population?
A. Ethnography
B. Grounded theory
C. Participatory action research
D. Phenomenology
33. Which qualitative study leads to proposed solutions to a given concern in a community?
A. Ethnography
B. Grounded theory
C. Participatory action research
D. Phenomenology
34. During interviews for qualitative research studies, which type of questions are utilized?
A. Answerable by 'Yes' or 'No'
B. Leading
C. Open-ended
D. True or False type
36. This is a collective term for the final format of the data following reduction analysis in a
qualitative research.
A. Brackets
B. Categories
C. Codes
D. Themes
For numbers 37-40, given the following characteristics and researches, choose the option specific
to a qualitative research design. Options may be used more than once.
A. Case study
B. Ethnography
C. Grounded theory
D. Phenomenology
41. An investigator documented three cases of lung carcinoma in among workers in a Security
Agency. This type of study is best described by:
A. Case-control
B. Case Report
C. Case Series
D. Cohort
42. What kind of Epidemiologic study should be done to determine the cause of an
unusual infection?
A. Analytic study
B. Descriptive study
C. Experimental study
43. Which research design is a detailed report of the unique symptoms, signs, diagnosis, treatment,
and follow-up of an individual patient?
A. Case Report
B. Case Series
C. Cross-Sectional Study
D. Ecologic Study
44. Which research design could be used to study multiple diseases and multiple exposures/risk
factors all at the same time?
A. Case Report
B. Case Series
C. Cross-Sectional Study
D. Ecologic Study
For numbers 46-50, choose from the options below the most appropriate research design for the
following descriptions. Options may be used more than once.
A. Case-Control Study
B. Cohort Study
C. Cross-Sectional Study
D. Ecologic study
46. The objective is to determine prevalence and the relationship between factor and outcome.
47. Objective is to test hypothesis and the disease of interest is rare.
48. Objective is to test hypothesis and the exposure is rare.
49. A study that examines the occurrence of disease in a defined population at a particular point in time.
50. The purpose of the study is to assess burden of disease in a population.
**END OF EXAMINATION**